மீ ராபர்ட் பெச்சார்ட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மீ ராபர்ட் பெச்சார்ட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மீ ராபர்ட் பெச்சார்ட் Today - Breaking & Trending Today

DGAP-News: Altus Formulation Inc.: Altus Formulation Announces Allowance of New Flexitab Technology Patent in USA


DGAP-News: Altus Formulation Inc.: Altus Formulation Announces Allowance of New Flexitab Technology Patent in USA
vom 15.04.2021, 13:00 Uhr
Bild: pixabay.com
Altus Formulation Inc.: Altus Formulation Announces Allowance of New Flexitab Technology Patent in USA
15.04.2021 / 13:00
Altus Formulation Announces Allowance of New Flexitab Technology Patent in USA
New USA Patent Complements Existing Global Flexitab Portfolio
LAVAL, QC / ACCESSWIRE / April 15, 2021 / Altus Formulation Inc. ( Altus ) today announced that its patent application US 2020029785 covering all Flexitab Breakable Extended Release Tablets has been allowed by the United States Patent and Trademark Office. The new patent is expected to provide protection to Flexitab products in the USA until 2038. ....

United States , M Robert Bechard , Damon Smith , Altu Trazoflex , Trademark Office , Corporate Development , Altus Formulation Inc , Distribution Services , Altus Formulation , Formulation Inc , Altus Formulation Announces Allowance , New Flexitab Technology Patent , Formulation Announces Allowance , Flexitab Breakable Extended Release Tablets , United States Patent , Robert Bechard , Corporate News , Regulatory Announcements , ஒன்றுபட்டது மாநிலங்களில் , மீ ராபர்ட் பெச்சார்ட் , டாமன் ஸ்மித் , முத்திரை அலுவலகம் , பெருநிறுவன வளர்ச்சி , அல்டஸ் உருவாக்கம் இன்க் , விநியோகம் சேவைகள் , அல்டஸ் உருவாக்கம் ,

Altus Formulation Inc.: Altus Formulation Announces Allowance of New Flexitab Technology Patent in USA


Altus Formulation Inc.: Altus Formulation Announces Allowance of New Flexitab Technology Patent in USA
New USA Patent Complements Existing Global Flexitab Portfolio
LAVAL, QC / ACCESSWIRE / April 15, 2021 / Altus Formulation Inc. ( Altus ) today announced that its patent application US 2020029785 covering all Flexitab Breakable Extended Release Tablets has been allowed by the United States Patent and Trademark Office. The new patent is expected to provide protection to Flexitab products in the USA until 2038.
Speaking about the new patent Dr. Damon Smith CEO of Altus said; We are very pleased to have achieved this major milestone for Flexitab technology so quickly, providing as it does a further 12 years of patent coverage to Altus TrazoFlex, TramaFlex and AcetraFlex late stage opportunities . He added; There are many titration sensitive drugs on the market today especially in the CNS space. Flexitab s ability to generate multiple extended-release doses from a sing ....

United States , M Robert Bechard , Kostenloser Wertpapierhandel , Damon Smith , Altu Trazoflex , Trademark Office , Corporate Development , Altus Formulation Inc , Altus Formulation , Flexitab Breakable Extended Release Tablets , United States Patent , Robert Bechard , ஒன்றுபட்டது மாநிலங்களில் , மீ ராபர்ட் பெச்சார்ட் , டாமன் ஸ்மித் , முத்திரை அலுவலகம் , பெருநிறுவன வளர்ச்சி , அல்டஸ் உருவாக்கம் இன்க் , அல்டஸ் உருவாக்கம் , ஒன்றுபட்டது மாநிலங்களில் காப்புரிமை , ராபர்ட் பெச்சார்ட் ,

Altus Formulation Inc.: Cadila Pharmaceuticals and Altus Formulation Announce Successful Clinical Studies with TramaFlex Breakable Extended-Release Tablets


Altus Formulation Inc.: Cadila Pharmaceuticals and Altus Formulation Announce Successful Clinical Studies with TramaFlex Breakable Extended-Release Tablets
tm Modified Release Technology Platform:
New Safer to Use Value Added Tablets
AHMEDABAD, INDIA and LAVAL, QC / ACCESSWIRE / January 27, 2021 / Cadila Pharmaceuticals Limited (
Cadila ) and
Altus ) today announced the successful completion of human clinical studies with TramaFlex
TM breakable extended-release (ER) tablets, a novel value-added once-daily formulation of tramadol hydrochloride for the improved treatment of patients with moderate to moderately severe pain.
Developed by Altus using proprietary AmyloFlex
TM technology, human bio-equivalence studies conducted by Cadila demonstrated TramaFlex ER tablets are bio-equivalent to 24hr ER products available commercially in North America, Europe, and Asia. Unlike marketed brands that can rapidly release their entire contents if damaged, with ....

United States , M Robert Bechard , Kostenloser Wertpapierhandel , Damon Smith , Cadila Pharmaceuticals Limited , Corporate Development , Technology Platform , Altus Formulation Inc , Cadila Pharmaceuticals Ltd , Cadila Pharmaceuticals , Successful Validation , Modified Release Technology Platform , New Safer , Use Value Added , Altus Formulation , North America , Rajiv Modi , Robert Bechard , ஒன்றுபட்டது மாநிலங்களில் , மீ ராபர்ட் பெச்சார்ட் , டாமன் ஸ்மித் , காடிலா மருந்துகள் வரையறுக்கப்பட்டவை , பெருநிறுவன வளர்ச்சி , தொழில்நுட்பம் நடைமேடை , அல்டஸ் உருவாக்கம் இன்க் , காடிலா மருந்துகள் லிமிடெட் ,